SCHEMBL1008946

SCHEMBL1008946

COc1ccc(Oc2cnn(C(CC3CCCCC3)C(=O)O)c(=O)c2)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.37
GCK P35557 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CTSD P07339 4/20 0.36
GPR6 P46095 1/20 0.36
ELANE P08246 1/20 0.35
CHRM4 P08173 2/20 0.35
NPBWR1 P48145 2/20 0.35
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
MAPK14 Q16539 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
TTK P33981 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008176 0.89 NPBWR1 (0.41) PTGDR2GCKNPC1RAB9AELANE
SCHEMBL1008076 0.89 BRD4 (0.39) CHRM4MAPK14
SCHEMBL1007921 0.86 NPBWR1 (0.44) GCKNPC1RAB9ANPBWR1CTSL
SCHEMBL1007288 0.86 LPAR1 (0.41)
SCHEMBL1009446 0.84 NPBWR1 (0.37) GCKNPC1RAB9ANPBWR1CTSL
SCHEMBL1008741 0.84 LPAR1 (0.39)
SCHEMBL1008255 0.84 CTSS (0.39) GCKRAB9ANPBWR1CTSLCTSS
SCHEMBL1010743 0.83 GCK (0.36) GCK
SCHEMBL1008488 0.83 GCK (0.36) GCKCHRM4CTSS
SCHEMBL1008683 0.83 EGLN1 (0.41) PTGDR2GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK PTGDR2 1648/4885GCK 1/4885NPC1 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.